Context: Expression of microRNAs (miRs) related to bone metabolism in the serum may be affected by antiosteoporotic treatment.
M icroRNAs (miRs) are small noncoding RNAs ;20 nucleotides long that regulate gene expression at the posttranscriptional level. Binding of miRs to their target messenger RNAs (mRNAs) through complementary sequences enhances mRNA degradation or translation repression according to the degree of miR and mRNA complementarity. MiRs have been reported to regulate a wide range of biological processes, such as development, differentiation, cell proliferation, cell apoptosis, and metabolism (1, 2) and are implicated in the pathophysiology of various disorders, including cancer, neurologic and muscular disorders, autoimmune diseases, inflammation, cardiovascular disorders, and diabetes (3) .
Several studies have demonstrated a role of miRs in osteoblast and osteoclast differentiation and function (4-7) through controlling the expression of key regulators of bone metabolism, including runt-related transcription factor 2 (Runx2) (8) and Wnt signaling (9) .
Analysis of specific miR signatures promises a potential novel, valuable tool in diagnostics and therapeutics in the bone field (10, 11) . We (12) and others (7, 13) have described associations of several circulating miRs with bone mineral density (BMD) or prevalent fractures in postmenopausal osteoporotic women (14) . Moreover, tissue expression of certain miRs has been highly associated with their corresponding serum levels (7) , suggesting that circulating miR levels may directly reflect processes of bone metabolism at tissue level.
Specific miRs could be proved to be useful in investigating alterations of bone metabolism in osteoporosis and the response to antiosteoporotic treatment. However, data regarding the expression of miRs during treatment with antiosteoporotic agents are lacking. To elucidate this issue, we studied the differential expression of miRs linked to bone metabolism in postmenopausal women with low bone mass treated with two of the most potent antiosteoporotic agents available, namely denosumab (Dmab) (15) and teriparatide (TPTD) (16) , that exert opposite effects on bone remodeling but are both highly effective in increasing BMD and decreasing fracture risk.
Patients and Methods

Study design
This was a single-center study of 60 postmenopausal women (mean age, 65.8 6 8.6 years; range, 54 to 85 years) with low bone mass who were recruited and monitored regularly throughout the study at the outpatient clinics for metabolic bone diseases of the 424 General Military Hospital, Thessaloniki, Greece. Patients received either TPDT (20 mg/d, n = 30) or Dmab (60 mg/6 months, n = 30) for 12 months. All patients were supplemented with calcium at 1000 mg/d and vitamin D at 800 IU/d throughout the study. Exclusion criteria were: (1) history or presence of bone disease other than primary osteoporosis (e.g., hyperparathyroidism, Paget disease of bone, osteogenesis imperfecta), (2) medication known to affect bone metabolism (e.g., glucocorticoids) within the last 3 years, with the exception of previous antiosteoporotic treatment, (3) hip fracture or hip or knee replacement within 6 months before enrollment, (4) history of high-energy fractures, (5) any type of cancer, (6) renal and/or liver failure, (7) diabetes mellitus, (8) uncontrolled thyroid disease, and (9) primary ovarian failure.
A low-energy fracture was defined as a result of falling from standing height or less, whereas a high-energy fracture was defined as any other type of trauma (e.g., falling from height higher than standing height, motor vehicle accident) (17) . The quantification of BMD (g/cm 2 ) at baseline and 12 months after treatment initiation was performed by dual energy X-ray absorptiometry at the lumbar spine (LS) (L1-L4) using a DPX-IQ densitometer (Lunar Corporation, Madison, WI). At baseline and at 12 months all participants were also subjected to standardized radiographs in anteroposterior and left lateral projections of the thoracolumbar spine and were asked about a history of fracture at nonvertebral sites. All radiographs were examined by one experienced skeletal radiologist (K.K.) and a member of the study team 
Sample processing
Previously unthawed serum samples (stored at 280°C) obtained at baseline and at 3 months and 12 months after treatment were analyzed in one batch at the end of the study. Two hundred microliters from each sample was used for purification of cell-free total RNA, primarily miR by an miRNeasy serum/plasma kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions.
Reverse transcription (RT) was performed with the miScript II RT kit (Qiagen). A panel of three invariant miRs, two small nucleolar RNAs (SNORD95, SNORD96A), and one small nuclear RNA (RNU6-2) was used to normalize for variability in sample loading and real-time RT-polymerase chain reaction (PCR) efficiency.
Cycling was performed under standardized conditions with 23 QuantiTect SYBR Green PCR master mix on the Qiagen Rotor-Gene Q (Corbett Rotor-Gene 6000) real-time PCR cycler. Performance of PCR was done in triplicates.
Quality control
To determine the efficiency of RNA extractions and/or the presence of inhibitors in complementary DNA synthesis or in PCR, we quantified the levels of the spike-in control (a Caenorhabditis elegans miR-39 miR mimic) added before RNA extraction by realtime PCR. All complementary DNAs expressed the spike-in control at normal levels [cycle threshold (C t ) , 22 cycles]. Statistical analysis confirmed the absence of outliers in the C t values for the spike-in.
Biochemical assays
All assays were measured by a second-generation electrochemiluminescence immunoassay on a Cobas e411 automated analyzer (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions.
The measurement range and total analytical imprecisions in our laboratory for the measured bone parameters are: intact parathyroid hormone (PTH), 1.2 to 5000 pg/mL and ,4.0%, respectively; C-terminal cross-linking telopeptide of type I collagen (b-CTX), 10 to 6000 ng/L and ,3.5%, respectively; total procollagen type 1 N-terminal propeptide (P1NP), 5 to 1200 ng/mL and ,4.5%, respectively; total 25-hydroxyvitamin D levels, 3 to 100 ng/mL and ,4.7%, respectively.
Selection of miR primer assays
Selection of miRs was based on existing literature on specific miRs that were reported to correlate with bone metabolism both in serum and tissue samples. Additionally, the databases (1) miRBase (18), (2) DIANA Tools (19) , (3) PicTar (20), (4) miRDB (21), (5) TargetScanHuman (22), (6) miRGator (23), and (7) miR (24) were searched to identify biological targets of miRs in humans, searching for 8mer, 7mer, and 6mer sites that match the seed region for each miR, using conserved sites and the best cumulative scores. Sixteen miRs that fulfilled the above criteria were finally selected for analysis (Supplemental Table 1 ).
Statistical analysis
Resultant data on mean C t values for each miR were exported and uploaded to the Qiagen Web site for analysis (miR primer assay data analysis version 3.5, GeneGlobe data analysis), where a classic DDC t calculation and a log 2 transformation provided normalized fold-difference values for the miR targets as previously described (12) . The P values were calculated based on a Student paired t test of the replicate 2 2DDC(t) values for each gene in different time points within each group of patients.
Data on biochemical and anthropometric results are given as mean 6 standard deviation. A paired t test or Wilcoxon signed rank test was used to test for differences at different time points within the two groups.
A Pearson correlation coefficient or Spearman rank correlation coefficient was used for associations between relative serum miR expression and bone parameters of the study population, as applicable.
Multiple linear regression was used to test whether the expression of specific miRs that significantly correlated with BMD at 12 months remained significant after adjustment for confounders. All P values are two sided, and a value of P , 0.05 was considered significant. All statistical analyses were performed using the Statistical Package for the Social Sciences version 23.0.
Results
Patient characteristics
All anthropometric, baseline biochemistry and BMD values are depicted in Table 1 . Dmab-treated patients and 40% (12 of 30) of TPDT-treated patients were treatment naive at baseline. The vast majority of the pretreated patients (16 of 18, 83%) of the TPTD treatment group had received either one bisphosphonate (mainly alendronate) or a sequential combination of bisphosphonates, whereas the remaining patients (3 of 18, 17%) had received strontium (2 of 18) and Dmab (1 of 18). The mean duration of pre-TPTD treatment was 5.9 years (range, 0.2 to 15 years).
Approximately 30% of the patients in both groups had a prevalent vertebral fracture whereas 13% of the Dmab-treated and 26% of the TPDT-treated patients reported prevalent nonvertebral fractures.
TPDT-treated patients had more severe bone loss according to BMD measurements and fracture history, in accordance with the current clinical practice within the Greek health care setting, which requires severe osteoporosis and/or inadequate response to previous antiosteoporotic treatment in order for TPTD to be administered.
TPTD treatment group
As expected, TPDT-treated patients had significant increases in serum levels of P1NP and b-CTX at 3 and 12 months and significant BMD gains in the LS at 12 months following treatment initiation (all P , 0.001) (Fig. 1) . None of the patients experienced a new vertebral or nonvertebral fracture during the study period.
Most TPDT-treated patients (n = 24) expressed all tested miRs. Decreased relative expression of miR-33-3p and miR-133a-3p during TPTD treatment At 3 months of treatment with TPTD we observed changes in the expression of 6 out of the 16 measured circulating miRs compared with baseline. Namely, miR23a-3p (4.5-fold change) and miR-124-3p (2.5-fold change) were increased, albeit not significantly, whereas miR-24-2-5p, miR-33-3p, miR-222-5p, and miR-503 were decreased, with miR-33-3p (0.71-fold change) reaching statistical significance (P = 0.03). At 12 months we observed changes in the expression of two miRs compared with baseline: miR-23-3p was increased (2.5-fold change; P = not significant) whereas miR-133a was decreased (0.76-fold change, P = 0.04) ( Table 2 ). There were no changes in the expression of miRs between 3 and 12 months of treatment.
When TPTD-treated patients were divided in treatment naive (n = 12) and pretreated (n = 18), no differences in the relative expression of circulating miRs were found between the two subgroups at any time point. Significant correlation of miR-124-3p relative expression with BMD changes during TPTD treatment BMD values at 12 months were significantly and inversely correlated with the relative serum expression of miR-124-3p at 3 months (r = 20.537, P = 0.0080) and 12 months (r = 20.536, P = 0.0076). Regression analysis showed that the relative expression of miR-124-3p in the serum at 3 months predicted BMD at 12 months of TPTD treatment after adjusting for age, previous antiosteoporotic treatment, and the presence of a prevalent vertebral fracture (Table 3) .
Correlations of miR-24-3p and miR-27a relative expression with changes in bone turnover markers during TPTD treatment
Relative serum expression of miR-24-3p at 3 months was significantly and inversely correlated with P1NP values at 3 and 12 months (r = 20.504, P = 0.12 and r = 20.451, P = 0.027, respectively) and with b-CTX values at 12 months (r = 20.414, P = 0.044). On the contrary, relative serum expression of miR-27a-3p at 3 months was positively correlated with b-CTX values at the same time point (r = 0.417, P = 0.043).
Dmab treatment group
Dmab-treated patients also experienced significant BMD gains in the LS at 12 months of treatment (all P , 0.001) along with the anticipated decreases in serum P1NP and b-CTX levels (P , 0.001) (Fig. 1) . The increase of LS BMD at 12 months did not differ between TPTD and Dmab (P = 0.232). None of the Dmab-treated patients experienced a new vertebral or nonvertebral fracture throughout the study period. Most Dmab patients (n = 24) also expressed all tested miRs.
None of the measured miRs changed significantly at 3 or 12 months of treatment with Dmab ( Table 2) .
Correlations of miRs related to osteoblastogenesis and osteoclastogenesis with changes in bone turnover markers during Dmab treatment
At 3 months of treatment, we found significant negative correlations between b-CTX changes and the relative expression of miRs related to osteoclastogenesis (namely 21-5p and miR-222), to osteoblastogenesis (namely miR-23a-3p), and to both osteoclastogenesis and osteoblastogenesis through regulation of the Wnt signaling pathway activity (namely miR-26a-5p, miR-27a, and miR-335-5p) (Supplemental Table 1 ; Table 4 ). Among those, miR-21-5p and miR-23a-3p remained significantly correlated with b-CTX levels at 12 months of treatment (Table 4) . On the contrary, P1NP levels were not correlated with the relative expression of measured miRs at any time point. There was no association between BMD values or BMD percentage changes at 12 months and the relative expression of miRs at any time point.
Discussion
In the present study we sought evidence of changes in the relative expression of miRs known to be associated with bone metabolism in the serum of postmenopausal women with low bone mass during treatment with two potent antiosteoporotic agents with opposite effects on bone turnover. We found significant differences in the expression profile of serum miRs during treatment with TPTD and Dmab, possibly reflecting the different mechanism of action of the two agents.
Patients treated with TPTD had decreased expression of miR-33 at 3 months and miR-133 at 12 months of treatment pointing to the posttranscriptional regulation of the respective genes by TPTD. MiR-33 is an intronic miR located in the gene sequences of organisms ranging from Drosophila to humans (25) . In humans it appears that miR-33 is highly conserved as a regulator of the dickopff-1 (DKK-1) gene, thus regulating Wnt signaling activity and consequently affecting both osteoblastogenesis and osteoclastogenesis, and it is also involved in lipid and cholesterol metabolism, by targeting the transcription factor sterol-regulatory element-binding protein (26) , and in the regulation of PTHrP at the tissue level as a tumor suppressor in lung cancer (27) . Alternatively, miR-133a in humans directly targets and inhibits the RUNX-2 gene, therefore affecting osteoblastogenesis, and it is also a potent regulator of the SLC39A1 (ZIP1) gene, which regulates the function of zinc transporters in osteoclasts (28) .
We hypothesize that TPTD-induced bone formation may involve different intracellular pathways in time. We base this hypothesis on the differences of circulating miRs at 3 and 12 months after treatment compared with baseline values, although we did not find a differential regulation of miRs between months 3 and 12. However, this could be because the changes between month 3 and month 12 failed to reach statistical significance.
According to our hypothesis, early after treatment initiation, TPTD may regulate Wnt signaling through both transcriptional and posttranscriptional control of the Wnt inhibitor DKK-1. PTH directly decreases expression of the DKK-1 gene, thus increasing Wnt signaling activity (29, 30) . Our results suggest that apart from the direct effects of PTH on DKK-1 gene suppression, posttranscriptional regulation of DKK-1 by decreasing miR-33 and thus diminishing the negative effects on DKK-1 gene expression offers an alternative regulatory mechanism enhancing optimal control of the Wnt signaling pathway. This is in line with previously reported increased DKK-1 levels in the serum of patients treated with TPDT (31, 32) . Later during treatment, decreased miR-133a relative expression may contribute to the continued anabolic response of TPDT by activating RUNX-2 gene expression given that PTH increases Runx2 mRNA and protein levels and activates a protein kinase A-dependent increase in Runx2 activity (33) (34) (35) (36) . MiR-133a has been described before in the serum of osteoporotic patients. More specifically, miR-133a expression was increased in peripheral monocytes of patients with low BMD compared with healthy controls (37) , and in the serum of postmenopausal women with osteoporotic fractures compared with nonfractured women (38) , suggesting an inverse relationship with bone health. These findings are in line with our observations, as a decrease in miR-133a is expected following treatment with an anabolic agent leading to BMD improvement.
In our study, miR-124-3p did not significantly change with TPTD treatment, but it was identified as an early, independent negative predictor of BMD changes at 12 months; for example, the lower the expression of miR-124-3p at 3 months the higher the BMD response to TPTD treatment. MiR-124-3p has been reported to inhibit both osteoclastogenesis, by suppressing nuclear factor of activated T cells 1 and the receptor activator of nuclear factor k-B ligand-mediated osteoclast differentiation (5) Table 1 ), and osteoblastogenesis, by suppressing the distal-less (DLX) (6) family of transcription factors. Thus, the lower miR-124-3p levels would be expected to result in higher TPDT-induced stimulation of osteoclastogenesis and osteoblastogenesis and, therefore, greater BMD gains, which is in line with our findings. We had previously described increased serum miR-124-3p levels in postmenopausal women with osteoporosis compared with women with normal BMD (12) .
In contrast to TPTD, Dmab did not significantly change serum levels of the tested miRs. We do not have a solid explanation for this lack of changes. We could only speculate that it could be attributed to differences in the pharmacokinetics of the two agents. Another hypothesis is that we might have missed changes of miRs related to Dmab-induced decreased osteoclastogenesis because our prespecified panel of miRs included mainly miRs related to osteoblastogenesis, given that the latter were until now better investigated (39) .
Interestingly, levels of b-CTX were correlated with different miRs at the two treatment groups. In TPDT-treated patients, serum b-CTX levels at 3 and 12 months of treatment were correlated with miR-27a and miR-24-2-5p, respectively. In Dmab-treated patients, miRs mostly associated with osteoclast differentiation and function were associated with b-CTX levels at both time points. These differences probably reflect the different molecular mechanisms through which TPTD and Dmab affect bone resorption as assessed by the measurement of b-CTX in the serum.
The main strength of this study was the investigation, for the first time in the literature to the best of our knowledge, of changes in the relative serum expression of miRs known to be associated with bone metabolism in postmenopausal women during antiosteoporotic treatment. Our study has several limitations. First, owing to its open-label design we had different baseline BMD values between the two groups; however, current clinical practice within the Greek health care setting requires more severe osteoporosis in order for TPTD to be administered. Second, although more than half of the TPTD-treated patients were not treatment naive, changes in the relative expression of miRs did not differ according to previous treatment in TPTD group. Third, the number of patients included as well as the duration of our study was relatively short, as this was an exploratory study. Fourth, BMD was measured only in the LS; however, given the short duration of the study and the predominantly trabecular composition of the spine, LS was the measurement site that was expected to reveal the more prominent BMD changes at 12 months. Additionally, we performed lateral X-rays of the spine at baseline and 12 months so that we could detect any degenerative alterations that could artificially affect the result of the BMD measurement. Finally, we selected specific miRs expressed in the serum instead of a microarray-based screening owing to budget restrictions.
In conclusion, we report substantial changes of several miRs that regulate osteoblast and osteoclast differentiation and function following treatment with antiosteoporotic agents. Their stability and resistance to RNases in biological fluids render miRs promising protein-based biomarkers that could detect earlier than conventional markers alterations on bone metabolism (40) . Larger studies are certainly needed to confirm the utility of a specific miR signature in the serum as an early and reliable index of treatment monitoring.
